<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193761</url>
  </required_header>
  <id_info>
    <org_study_id>HAM00077</org_study_id>
    <nct_id>NCT04193761</nct_id>
  </id_info>
  <brief_title>TAURINE and HCC PATIENTS</brief_title>
  <official_title>COMPARISON BETWEEN SERUM TAURINE AND SPECIFIC TUMOR MARKERS FOR EARLY DETECTION AND DIAGNOSIS OF HCC IN EGYPTIAN PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serum taurine level beside (AFP and AFU) are of great value in early diagnosis in HCC
      Egyptian patients and may have a rule in identifying end-stage liver disease (ESLD) patients
      candidate for LDLT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Taurine has been demonstrated to have a direct and indirect antioxidant effect and to display
      antineoplastic activity by preventing angiogenesis and enhancing tumor cell apoptosis. Also
      it was suggested that measurement of serum taurine level in hepatic patients beside fibroscan
      is of great value in the early diagnosis of any fibrotic and cancerous liver changes.Aim of
      the work was to correlate serum taurine level with the levels of the specific tumor markers
      (α- fetoprotein and α-L-fucosidase ) for early diagnosis of different stages of HCC in
      Egyptian patients.

      This observational case-control study was conducted in the Tropical Medicine Department,
      Ahmed Maher Teaching Hospital. Eighty hepatic patients were assigned to three groups (Chronic
      hepatitis, Cirrhosis and HCC). Twenty healthy subjects were enrolled as a control group.
      Serum levels of AFP, AFU, and taurine beside complete biochemical analysis and liver biopsies
      from all selected patients were done. Patients who accepted to be a candidate for living
      donor liver transplant (LDLT) were referred to Ain Shams University Specialized Hospital
      (ASUSH) liver transplant unit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Actual">October 25, 2018</completion_date>
  <primary_completion_date type="Actual">April 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Taurine level among patients groups</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Taurine in HCC</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic hepatitis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatocellular carcinoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>taurine level</intervention_name>
    <description>Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.</description>
    <arm_group_label>Chronic hepatitis</arm_group_label>
    <arm_group_label>Cirrhosis</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Hepatocellular carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis

          -  Cirrhosis

          -  HCC patients

        Exclusion Criteria:

          -  Patient refusal

          -  Bleeding tendency

          -  Tense ascites

          -  Inability to obtain a liver biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hanaa El Gendy</name>
      <address>
        <city>Cairo</city>
        <state>Ain Shams University Specialized Hospital</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 7, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hanaa Mohamed Abdallah ElGendy MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

